Abstract
Objective The objective of this study was to examine the prescribing of Chinese herbal medicine (CHM) by licensed acupuncturists in the United States during the COVID-19 pandemic.
Methods A 28-question survey with nine branching questions was disseminated through collegial networks, paid advertisements, and a study website in April-July 2021. Participants indicated they were licensed acupuncturists that treated more than five patients for symptoms likely related to COVID-19 to gain entry to the full survey. Surveys were undertaken electronically through the Research Electronic Data Capture (REDCap) system.
Results The survey was undertaken by 103 participants representing all US geographic regions, and had an average of 17 years in practice. Sixty-five percent received or intended to receive the COVID-19 vaccine. Phone and videoconference were the predominant methods of patient contact; granules and pill forms of CHM were the most commonly prescribed. A wide variety of information sources were used in devising patient treatments inclusive of anecdotal, observational, and scientific sources. Most patients were not receiving biomedical treatment. Ninety-seven percent of participants reported that they had no patients die of COVID-19, and the majority reported less than 25% of their patients developed long hauler syndrome (post-acute sequelae SARS-CoV-2 infection).
Conclusions This study demonstrates that licensed acupuncturists were treating COVID-19 infected individuals in the US during the early stages of the pandemic, and for many such patients this was the only therapeutic intervention they had access to from a licensed healthcare provider. Information disseminated from China through collegial networks, along with published sources including scientific studies, informed the approach to treatment for the vast majority of the acupuncturists surveyed. This study provides insight into an unusual circumstance in which clinicians needed to establish evidence-based approaches to the treatment of a new disease in the midst of a public health emergency.
Strengths and Limitations of the Study
Detailed survey that was widely disseminated through paid advertisements and a study web site
Data was only collected from licensed clinicians who had treated more than five patients with symptoms likely related to COVID-19
Survey was undertaken through the Research Electronic Data Capture (REDCap) system
Statistical analysis was undertaken to determine associations between question responses
The survey was not psychometrically tested
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Institutional Review Board of Albert Einstein College of Medicine gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.